TREATMENT OF ASPERGILLUS INFECTIONS WITH ALPHA THYMOSIN PEPTIDES
Granted: November 22, 2012
Application Number:
20120295840
A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.
PREVENTION OR DELAY OF ONSET OF ORAL MUCOSITIS
Granted: October 6, 2011
Application Number:
20110245316
The present invention provides a method for preventing or delaying the onset of oral mucositis, including the onset of ulcerative or severe OM, in a patient receiving cancer therapy. The method comprises administering to the patient an effective regimen of ?-D-glutamyl-L-tryptophan (SCV-07) over the course of therapy. The regimen, which includes scheduled doses of SCV-07 with respect to radiation exposure and/or chemotherapy, is effective for preventing or delaying the onset of OM. In…
Treatment or Prevention of Hepatitis C with Immunomodulator Compounds
Granted: August 18, 2011
Application Number:
20110200558
A method of treatment for treating or preventing hepatitis C (HepC) in a target subject, including administering to the target subject an effective amount of an immunomodulator compound of Formula A wherein, n is 1 or 2, R is hydrogen, acyl, alkyl or a peptide fragment, and X is an aromatic or heterocyclic amino acid or a derivative thereof, wherein; (i) the immunomodulator compound is administered to the subject at a dosage of greater than 0.001 mg/kg; (ii) the immunomodulator…
Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa
Granted: May 19, 2011
Application Number:
20110117211
An immunomodulatory compound is utilized to treat mucosa disease.
TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH ANTIBODIES AGAINST CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4)
Granted: December 30, 2010
Application Number:
20100330093
Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4).
TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH AN ANTINEOPLASTIC HEAT SHOCK APOPTOSIS ACTIVATOR (HSAA)
Granted: December 16, 2010
Application Number:
20100317583
Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and/or optionally one or more additional anti-melanoma agents.
TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS WITH ALPHA THYMOSIN PEPTIDES
Granted: December 9, 2010
Application Number:
20100311656
An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.
ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS
Granted: November 11, 2010
Application Number:
20100285060
The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer…
TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR
Granted: October 21, 2010
Application Number:
20100267637
Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor.
METHOD OF ADMINISTERING A THYMOSIN ALPHA 1 PEPTIDE
Granted: September 2, 2010
Application Number:
20100221274
A Thymosin alpha 1 (TA1) peptide is administered to a patient in need of immune stimulation so as to substantially continuously maintain an immune stimulating-effective amount of the TA1 peptide in the patient. The administration method may be by continuous infusion.
TREATMENT OF ALLERGIC DISEASE WITH IMMUNOMODULATOR COMPOUNDS
Granted: August 12, 2010
Application Number:
20100204295
A method of treatment for treating, preventing, inhibiting or reducing allergic disease or its effects in a subject, comprises administering to the subject an effective amount of an immunomodulator compound, which composes an aromatic or heterocyclic amino acid residue or a derivative thereof. Preferably, the immunomodulatory compound is a dipeptide which comprises a D- or L-tryptophan residue.
Alpha Thymosin Peptides as Cancer Vaccine Adjuvants
Granted: April 15, 2010
Application Number:
20100092499
A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject; and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the cancer vaccine and the alpha thymosin peptide can be administered separately or together.
METHOD OF TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE DUE TO DISEASE OF MUCOSA
Granted: April 8, 2010
Application Number:
20100086622
An immunomodulatory compound is utilized to treat mucosa disease.
Treatment of Melanoma With Alpha Thymosin Peptides
Granted: January 21, 2010
Application Number:
20100016211
A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level.
Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds
Granted: June 4, 2009
Application Number:
20090143313
An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.
TREATMENT OF MELANOMA
Granted: April 2, 2009
Application Number:
20090088392
An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.
Immunomodulator Compounds as Vaccine Enhancers
Granted: March 19, 2009
Application Number:
20090074815
A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine.
Treatment of Melanoma with Alpha Thymosin Peptides
Granted: December 4, 2008
Application Number:
20080300166
A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level.
Thymosin Alpha 1 Peptide/Polymer Conjugates
Granted: June 26, 2008
Application Number:
20080152668
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in…
Treatment of aspergillus infections with alpha thymosin peptides
Granted: June 7, 2007
Application Number:
20070129292
A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.
